AUTOFLEET/BLUEBIRD/ABEAM
22.4.2021 15:02:11 CEST | Business Wire | Press release
Bluebird Group (Bluebird), Indonesia’s leading taxi operator, has engaged with Autofleet and ABeam Consulting for a project to support its national fleet of over 23,000 vehicles with Autofleet’s Vehicle-as-a-Service platform. Bluebird and Autofleet have entered into a commercial agreement that is scheduled to roll out for vehicles operating in Jakarta and the surrounding area as soon as Q2 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210422005276/en/
By leveraging the Autofleet platform, Bluebird will be able to optimize its fleet’s vehicle placement, match and predict drivers based on demand forecasting to reduce empty rides, optimize allocation efficiency, allow for greater availability in traditionally under-served areas, reduce customer ETAs and improve overall customer experience. Autofleet is ingesting data from rides requested through the operator’s digital app and through traditional street hailing. These inputs are combined with real-time traffic data, weather forecasts, local events and other data points for increased demand prediction accuracy.
“The demand for mobility services has evolved, and it poses challenges that can only be solved by a combination of AI driven technology, and best in class operations. It is Bluebird’s value and commitment to deliver such customer-centric innovation through sustainable cooperation with our strategic partners, Autofleet and ABeam Consulting,” said Paul Soegianto, Chief Strategy Officer of PT Blue Bird Tbk.
In business for nearly 50 years, Bluebird serves millions of passengers every month. The fleet includes regular taxis (Bluebird & Pusaka), executive taxis (Silverbird), limousines and car rentals (Goldenbird), bus charters (Bigbird) and logistics (Birdkirim) among others. Autofleet’s platform will be integrated into the current dispatch infrastructure, supporting Bluebird, Silverbird and Birdkirim services in its first phase. In the longer term, the collaboration will inform Bluebird’s expanded activities in logistics and delivery services as well as exploration of new mobility infrastructure including electric vehicle (EV) charging.
“We are excited to partner with Bluebird, already a leader in mobility services in Southeast Asia, and apply the Autofleet platform to power current operations and prepare the business for future strategy and growth,” said Kobi Eisenberg, CEO at Autofleet. “Deploying Autofleet's platform will keep Bluebird at the cutting edge of the mobility industry, providing an outstanding customer experience, in a very competitive market.”
“ABeam Consulting is thrilled to support and expand Bluebird’s innovative services through AI and machine learning to increase operational efficiency,” said Tatsuya Kamoi, CEO at ABeam Consulting. “With our deep expertise in Mobility as a Service, we will support Bluebird’s operations and apply industry best practices to stay competitive with leading rideshare companies.”
In September 2020, Autofleet and ABeam Consulting entered a partnership to offer a comprehensive solution that supports Mobility as a Service (MaaS) projects end-to-end from the proposal stage to system implementation. Following projects in Japan and Cambodia, the engagement with Bluebird was secured through a year-long competitive proposal process and represents the largest commercial fleet management opportunity arising from the partnership to date.
About Autofleet
Autofleet provides the leading Vehicle-as-a-Service platform for fleets to optimize existing operations and to seamlessly launch new business models from existing assets. The platform leverages advanced machine-learning algorithms for demand prediction, optimized placement and matching, automated pit-stop management and in/de-fleeting, and more. For more information, please visit https://www.autofleet.io/
.
About ABeam Consulting
ABeam Consulting Ltd., headquartered in Tokyo having 6,600 people serve more than 1,100 clients throughout Asia, in the Americas and Europe with its 28 offices since 1981, providing consulting services across various industries and with an expertise in digital transformation services that create strategic advantage, improve business processes, leverage technology innovation and enhance organizational performance.
Please contact and visit us under https://www.abeam.com/jp/en for more details.
About Bluebird
Established in 2001, PT Blue Bird Tbk (BIRD), is a public transportation company catering to passengers and providing other land transportation services. PT Blue Bird Tbk's 15 subsidiaries are found in 18 major cities around the country, namely Jakarta, Depok, Tangerang, Bekasi, Cilegon, Medan, Manado, Bandung, Palembang, Balikpapan, Padang, Pangkalpinang, Batam, Bali, Lombok, Semarang, Surabaya, Pekanbaru, Makassar, Solo and Yogyakarta.
Bluebird is committed to always provide safe, reliable, and comfortable transportation with easy accessibility for its customers. Companies extensive network covers more than 600 exclusive taxi outlets placed in malls, shopping centers and other strategic places. Serving millions of passengers every month.
Since going public on the Indonesia Stock Exchange in 2014, PT Blue Bird Tbk has gained status as a reliable and trustworthy transportation partner.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210422005276/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release
Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d
Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release
New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel
HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 17:30:00 CEST | Press release
HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
